AZAFAROS-B.V.
16.7.2024 10:01:28 CEST | Business Wire | Press release
Azafaros B.V. today announced positive topline data from its RAINBOW study, a Phase 2 clinical trial investigating nizubaglustat in patients with a genetic diagnosis of either GM2 gangliosidosis or Niemann-Pick disease type C (NPC).
About the Trial
The trial was conducted across three sites in Brazil, involving 13 patients older than 12 years of age, with the aim of determining the safety, pharmacodynamics, and pharmacokinetics of two different doses of nizubaglustat. The results will guide the identification of the target dose for Azafaros’ planned Phase 3 pivotal studies.
With the 12-week, double-blind and placebo-controlled part of the study complete, patients have now entered the extension phase, where all participants receive the study drug.
The data from the RAINBOW study will be presented at the SSIEM Annual Symposium 2024, which will take place on 3 - 6 September in Porto, Portugal.
Stefano Portolano, CEO at Azafaros, said: “The results of the Phase 2 RAINBOW study mark a pivotal moment in the development of nizubaglustat. The dual mode of action sets nizubaglustat apart as a leap forward from other agents. We are excited by the results of the study and more than confident that nizubaglustat has the potential to become a convenient, life-changing therapy for patients affected by GM1 and GM2 gangliosidoses and NPC. Azafaros is thankful to the patients and their families for their important contribution to the RAINBOW study. Azafaros is now poised to embark on a global Phase 3 trial next year.”
Lead RAINBOW investigator, Roberto Giugliani, added: “We are pleased to report the completion of this important step in the development of a new therapy for GM2 gangliosidosis and Niemann-Pick disease type C, which delivers data to determine the best dosing of nizubaglustat and allows the planning of the next phase.”
In a statement, a representative from the Associação Niemann-Pick & Batten Brasil (ANPB), a patient organisation in Brazil, said there is an urgent need for new treatments for NPC.
"Current therapeutic options are limited and do not offer a definitive cure. Clinical research plays a crucial role in this process, allowing the development and evaluation of new therapies that can improve patients' quality of life and slow the progression of the disease. Therefore, we are excited about developing innovative and convenient therapies.”
About nizubaglustat
Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC).
Nizubaglustat has received the following designations and support:
United States Food and Drug Administration (FDA)
Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC.
Orphan Drug Designations (ODD) for GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC.
IND Clearance and Fast Track Designation for GM1/GM2 gangliosidoses and NPC
European Medicines Agency (EMA)
Orphan Medicinal Product Designation (OMPD) for the treatment of GM2 gangliosidosis.
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Innovation Passport for the treatment of GM1 and GM2 gangliosidoses.
About GM1 and GM2 Gangliosidoses
GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS), resulting in progressive and severe neurological impairment and early death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.
About Niemann-Pick Disease Type C (NPC)
Niemann-Pick disease type C (NPC) is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood.
About Azafaros
Azafaros is a clinical-stage company founded in 2018 by scientists with a deep understanding of rare genetic disease mechanisms, using discoveries made by scientists at Leiden University and Amsterdam UMC. Azafaros is led by a team of highly experienced industry experts and aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. The Azafaros team is dedicated to rapidly bring new drugs to the rare disease patients who need them. The company is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619007436/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NETSCOUT Reveals Qualitative Shifts in DDoS Attack Sophistication, Infrastructure Capacity, and Threat Actor Capabilities4.3.2026 12:05:00 CET | Press release
AI Adoption, coordinated botnets, and persistent hacktivists groups drove millions of attacks NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT), today released its second half of the year 2025 Distributed Denial-of-Service (DDoS) Threat Intelligence Report, revealing sophisticated attacker collaboration, resilient botnets, and compromised IoT infrastructure that drove more than eight million DDoS attacks worldwide – some as large as 30 terabits per second (Tbps) – marking a new era of hyper-scale, coordinated threat activity that continues to outpace global takedown efforts. Meanwhile, the accelerating growth of DDoS-for-hire services is empowering a broader range of threat actors, intensifying operational risk to digitally connected organizations and enterprises. Implications for security professionals extend far beyond volumetric concerns and include reconnaissance and adaptive evasion which challenge traditional defense paradigms. Organizations must match adversarial innovation with intelligen
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally4.3.2026 12:00:00 CET | Press release
Expansion Signals Acceleration in AI, Clinical Innovation, and International Growth WHOOP, the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the company continues to scale globally. The hiring expansion reflects a clear strategic priority: bolstering a team that will define the future of human performance and health technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304866977/en/ WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally “Right now, companies are debating whether to hire more people or just invest in AI,” said Will Ahmed, Founder and CEO of WHOOP. “We are doing both. We are doubling down on exceptional talent and doubling down on world-class AI tools because the combination is what wins. Health monitoring is becoming one of the most important p
Radian Arc, VNPT and Blacknut Launch GPU Infrastructure in Vietnam, Enabling Cloud Gaming and AI Services4.3.2026 11:00:00 CET | Press release
Radian Arc, part of inferX, Submer’s AI cloud and GPU infrastructure platform has partnered with VNPT, and COMIT, to launch Cloud Gaming powered by Radian Arc’s GPU Edge Platform and Blacknut’s global cloud gaming service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303986657/en/ Radian Arc, VNPT and Blacknut Launch GPU infrastructure in Vietnam, enabling cloud gaming and AI services This deployment expands Radian Arc and Blacknut’s global cloud gaming partnership into the Vietnam market with VNPT and lays the foundation for future AI-native services and sovereign infrastructure together with COMIT. The deployment represents a commercial proof point of Radian Arc’s carrier-embedded GPU model, combining monetizable consumer services today with scalable AI infrastructure that can support sovereign AI workloads. “With VNPT’s market reach and Blacknut’s premium gaming catalog we’re bringing the next generation of interacti
Hermes Reply Partners with Lavazza to Develop a New Digital and Efficient Manufacturing Model4.3.2026 10:45:00 CET | Press release
An integrated, data-driven platform powered by AI and Computer Vision to enhance quality, efficiency and traceability across production processes Hermes Reply, the Reply Group company specialising in digital transformation for manufacturing and supply chain, has partnered with Lavazza Group in the design and implementation of a new digital and efficient manufacturing model, aimed at strengthening operational capabilities, ensuring high quality standards and supporting the company’s industrial development strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304639969/en/ Artificial Intelligence and Computer Vision technologies play a key role in making quality controls and production process analysis along packaging lines more intelligent and flexible. Through advanced image analysis and anomaly detection systems, overall process quality becomes more efficient and adaptable. The initiative, entitled “A new digital and
OPEX® Corporation to Exhibit Advanced Warehouse Automation Solutions at LogiMAT 20264.3.2026 09:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, will exhibit its latest advancements in warehouse automation at LogiMAT 2026. The world’s largest trade show for intralogistics solutions and process management, LogiMAT will be held March 24 through 26 at the Stuttgart Trade Fair Center in Germany. “Our team looks forward to being onsite at LogiMAT and showcasing several of our leading warehouse automation solutions,” said Alex Stevens, President, Warehouse Automation, OPEX. “We’re proud to deliver cutting-edge systems that help our clients transform how they conduct business, and we appreciate the vast opportunity LogiMAT provides to share our offerings and expertise with event attendees.” At LogiMAT Hall 5 ‒ Stand B25, OPEX will demonstrate Sure Sort® X with Xtract, its award-winning, automated pack-out and order takeaway system. The OPEX Booth will also feature a static display of the company’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom